Beth Winke, MD
Physical Medicine & Rehabilitation · Chesapeake, VANPI 1003812082
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Collegium Pharmaceutical, Inc. at 26.4% of the total.
Across 144 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$667
- Electronic Waveform Lab, Inc.$287
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$268
- Scilex Pharmaceuticals Inc.$169
- Abbott$112
- Vertex$103
- plus $919 from 22 others
What the payments were for
- Food & beverage$2,526100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 36 | $667 |
| Electronic Waveform Lab, Inc. | 18 | $287 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $268 |
| Scilex Pharmaceuticals Inc. | 10 | $169 |
| Abbott | 6 | $112 |
| Vertex | 5 | $103 |
| Biodelivery Sciences International, Inc. | 7 | $96 |
| AbbVie(2 entities) | 5 | $92 |
| Fidia Pharma USA Inc. | 4 | $83 |
| GRT US Holding, Inc. | 4 | $78 |
| Pfizer | 5 | $65 |
| Bioventus LLC | 3 | $56 |
| Almatica Pharma LLC | 3 | $54 |
| Pacira Therapeutics, Inc. | 3 | $53 |
| Johnson & Johnson | 2 | $49 |
| AstraZeneca | 3 | $45 |
| Shionogi Inc | 2 | $30 |
| Kaleo, Inc. | 2 | $29 |
| Forte Bio-pharma LLC | 2 | $29 |
| Nevro Corp. | 1 | $24 |
| Zyla Life Sciences, Inc. | 2 | $23 |
| Averitas Pharma Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Curonix LLC | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
How this compares
$2,526 in reported general payments places this provider in the 85th percentile of 231 physical medicine & rehabilitation providers in Virginia.
See all physical medicine & rehabilitation providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fentanyl | 73 | $28,449 |
| OxycontinOxycodone Hcl | 29 | $23,146 |
| Buprenorphine | 63 | $12,267 |
| Xtampza ErOxycodone Myristate | 26 | $12,041 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 326 | $7,621 |
| Lidocaine | 34 | $6,663 |
| MovantikNaloxegol Oxalate | 15 | $5,508 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 168 | $4,463 |
| Oxycodone Hcl | 181 | $3,035 |
| Gabapentin | 180 | $1,774 |
| Morphine Sulfate ErMorphine Sulfate | 71 | $1,675 |
| Tramadol Hcl ErTramadol Hcl | 19 | $1,531 |
| Diclofenac Sodium | 29 | $1,093 |
| Hydromorphone Hcl | 52 | $1,075 |
| Methadone Hcl | 53 | $979 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $16 | $13,157108 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $667 | $12,04126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 231 physical medicine & rehabilitation providers in Virginia.
Other physical medicine & rehabilitation in Chesapeake
- Krishna Brahma Sastry TopalliChesapeake$1K
- Kovosh DastanWinchester$23K
- Stephanie ClopAldie$16K
- Daniel HellerWarrenton$12K
- Amanda MoranNorfolk$9K
- Abraham CherrickAlexandria$9K
- Mir AliRichmond$8K
- Derek BuckBluefield$7K
- Danielle CherrickMc Lean$6K
- Christopher TrowerVirginia Beach$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.